KRAS and non-small cell lung carcinoma: Currently, a phase II clinical study known as RAMP-202 aims to assess the effectiveness and safety of the combination treatment of VS-6766 (an RAF/MEK inhibitor) and defactinib in patients with advanced KRAS-mutant NSCLC who have experienced treatment failure with previous platinum chemotherapy and immunotherapy (Capelletto et al., 2022).